You're likely a reasonable candidate if: You've been symptomatic for more than 12 weeks with confirmed or highly probable prior SARS-CoV-2 infection Standard care has not produced adequate improvement You have a clear symptom cluster that maps to one or more of the mechanisms above You're willing to undergo baseline labs and ongoing clinical monitoring You understand that peptide therapy is an emerging not established intervention for this indication You may need to address other issues first if: Active autoimmune conditions are not yet stabilised You have unmanaged cardiovascular disease You're currently immunosuppressed for another reason You haven't yet tried evidence-based long COVID rehabilitation approaches The most important step is working with a clinician who understands both long COVID pathophysiology and peptide pharmacology not one who simply offers a generic protocol
The provider matters more than the molecule: sterility, verified concentration, correct dosing, and supervision are what separate a clinical result from a gamble
Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells
This is an important insight because it sets the stage, at least in principle, for MS potentially being triggered by subtle injury to CNS myelin rather than by a primary autoimmune assault
Our GLP-1 ID program applies these learnings by combining individualized GLP-1 dosing with ongoing medical guidance, personalized support, and resources designed to help patients manage side effects, stay consistent with treatment, and build sustainable habits for long-term health
